Thumbnail Image
Publication

Overall survival results from Ariel3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma

Coleman, R. L.
; 
Oza, A.
; 
Lorusso, D.
; 
Aghajanian, C.
; 
Oaknin, A.
; 
Dean, A.
; 
Colombo, N.
; 
Weberpals, J.
; 
Clamp, Andrew R
; 
Scambia, G.
... show 9 more
Citations
Altmetric:
Abstract
Authors
Coleman, R. L.
Oza, A.
Lorusso, D.
Aghajanian, C.
Oaknin, A.
Dean, A.
Colombo, N.
Weberpals, J.
Clamp, Andrew R
Scambia, G.
Leary, A.
Holloway, R.
Gancedo, M. A.
Fong, P.
Goh, J.
O'Malley, D.
Goble, S.
Maloney, L.
Ledermann, J.
Affiliation
The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston,
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Identified with Open Access button
Adobe PDF, 262.05 KB
Keywords
Type
Meetings and Proceedings
Citation
Coleman RL, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Overall Survival Results from Ariel3: A Phase 3 Randomized, Double-Blind Study of Rucaparib Vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma. International Journal of Gynecological Cancer. 2022 Dec;32:A3-A5. PubMed PMID: WOS:000899252300006.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626149
Embedded videos